A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Genentech

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT00096928

ACD3101g

Details and patient eligibility

About

This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Enrollment: 1,846 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
• Are being treated with or initiating Raptiva therapy at the time of enrollment
• Be able to provide written informed consent
• Be willing and able to fully to participate for the duration of patient follow-up (5 years)

Exclusion Criterion:

• Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment